Table 4. Acceptable methods of contraception for people of childbearing potential.
| Sexual abstinence and abstinence from heterosexual intercourse (for people with
female sexual reproductive organs) (periodic abstinence and withdrawal methods are not acceptable forms of contraception) |
| Bilateral oophorectomy and/or hysterectomy |
| Bilateral tubal ligation |
| Copper intra-uterine device (IUD) |
| Levonorgestrel-releasing IUD (e.g., Mirena, Skyla) |
| Male condom and occlusive cap (diaphragm or cervical/vault cap) with spermicidal
foam / gel / film / cream / suppository |
| Vasectomised partner (if sole partner) |
Recommendations are based on the Clinical Trials Facilitation and Coordination Group recommendations related to contraception and pregnancy testing in clinical trials 99 , excluding hormone-based contraceptives options due to potential drug interactions with rifampicin and/or clarithromycin. The contraceptive effects of levonorgesterel-releasing intra-uterine systems are unlikely to be effected by drug interactions, as the direct release of levonorgestrel into the uterine cavity is unlikely to be affected by drug interactions via enzyme induction 100 .